About Transmedics Group Inc
- Industry: Health Care
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.transmedics.com/
Frequently Asked Questions
What is the 52-week range for TMDX?
The 52-week high is $156 and the 52-week low is $60.105.
What is the P/E ratio for TMDX?
The Price to Earnings (P/E) ratio is 18.03.
What is the dividend yield for TMDX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 32.97%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 22.69%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.79.
Analyst Recommendation Trends
Wall Street analyst consensus for TMDX over the last few months:
Latest TMDX News
TransMedics Group (TMDX) Stock Looks Below Fair Value On Earnings
TransMedics Group has seen its share price slide in recent months after a strong multi‑year run, which raises an obvious question for you as an investor. Is the current US$78.64 price still aligned with what the company is earning today, or has sentiment moved ahead of the underlying profit story? Over the past 5 years the stock has gained about 157.4%, which puts real weight on whether the earnings profile can support where the valuation now sits. The business relies on turning highly...
TransMedics Group (TMDX) Could Be 19% Undervalued If Its Growth Narrative Holds
TransMedics Group (TMDX) has drawn investor attention after recent trading left the stock around $78.64, with returns down over the past month but higher over the past three months and three years. Short term momentum for TransMedics Group has faded, with the share price return down 5.76% over one day, 6.27% over the past week and 4.38% over the past month. At the same time, a 14.20% 90 day share price return and a 54.08% three year total shareholder return point to a stock where sentiment...
TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.
TransMedics Offers An Attractive Entry Point, With Upside Potential Outweighing Risks
TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform. Read more on TMDX stock here.
TransMedics: Waiting On 2027 Catalysts (Rating Upgrade)
TransMedics' clinical trials are only moving forward slowly, potentially delaying a critical growth catalyst. Read why TMDX stock is upgraded to a buy.
2 Stocks Down 28% and 34% to Buy and Hold
These companies' sell-offs may have gone too far.
TransMedics Group, Inc. (TMDX) Presents at 2026 Global Healthcare Conference - Slideshow
2026-09-15. The following slide deck was published by TransMedics Group, Inc.
TransMedics Group, Inc. (TMDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
TransMedics Group, Inc. (TMDX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 3:20 PM EDTCompany ParticipantsWaleed Hassanein -...
TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial Officer, effective September 21, 2026. Mr. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M to support the Company's next phase of global growth. He succeeds Gerardo Hernandez, who will transition to Commercial Strategic Adviso
TransMedics Group Appoints Fernando Araujo CFO, Effective Sept. 21; Reaffirms FY26 Revenue Range $737M - $757M
TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), the global leader in portable warm perfusion for donor organs for transplantation, today announced the appointment of Fernando Araujo as Chief Financial
TD Cowen Reiterates Buy on TransMedics Group, Maintains $120 Price Target
TD Cowen analyst Joshua Jennings reiterates TransMedics Group (NASDAQ:TMDX) with a Buy and maintains $120 price target.
Is TMDX Stock Worth Buying as Growth Meets Rising Margin Pressure?
TransMedics' rapid revenue growth and cheaper valuation face rising margin pressure as heavy investment raises execution risks.
Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?
TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-11 | Weill David | +1,336 | $81.63 | $109,058 |
| 2026-08-17 | TOBIN JAMES R | -18,000 | - | - |
| 2026-07-10 | Corcoran Nicholas | +17,784 | - | - |
| 2026-07-10 | Corcoran Nicholas | +11,727 | - | - |
| 2026-07-10 | Hernandez Gerardo | +26,153 | - | - |
| 2026-07-10 | Hernandez Gerardo | +17,246 | - | - |
| 2026-07-10 | Hassanein Waleed H | +112,984 | - | - |
| 2026-07-10 | Hassanein Waleed H | +49,669 | - | - |
| 2026-05-20 | Lovell Stephanie | +2,922 | - | - |
| 2026-05-20 | Weill David | +2,922 | - | - |
| 2026-05-20 | Basile Edward M | +2,922 | - | - |
| 2026-05-20 | Gunderson Thomas J. | +2,922 | - | - |
| 2026-05-20 | Kania Edwin | +2,922 | - | - |
| 2026-05-20 | TOBIN JAMES R | +2,922 | - | - |
| 2026-05-20 | RAINES MERILEE | +2,922 | - | - |
| 2026-05-19 | Forsyth Matthew S. | +23,171 | - | - |
| 2026-05-19 | Forsyth Matthew S. | +15,409 | - | - |
| 2026-03-04 | Lovell Stephanie | -1,193 | $149.62 | $178,497 |
| 2026-03-04 | Weill David | -3,571 | - | - |
| 2026-03-04 | Weill David | -3,571 | $146.82 | $524,294 |
| 2026-03-04 | Weill David | +3,571 | $14.2 | $50,708 |
| 2026-03-04 | Hernandez Gerardo | -5,912 | - | - |
| 2026-03-04 | Hernandez Gerardo | -1,324 | - | - |
| 2026-03-04 | Hernandez Gerardo | -5,912 | $147.21 | $870,306 |
| 2026-03-04 | Hernandez Gerardo | +5,912 | $69.84 | $412,894 |
| 2026-03-04 | Hernandez Gerardo | -1,324 | $147.21 | $194,906 |
| 2026-03-04 | Hernandez Gerardo | +1,324 | $77.12 | $102,107 |
| 2026-03-02 | Hernandez Gerardo | -375 | $139.12 | $52,170 |
| 2026-03-02 | Ranganath Anil P. | -864 | $139.12 | $120,200 |
| 2026-03-02 | Corcoran Nicholas | -2,966 | $139.12 | $412,630 |
| 2026-02-18 | Cecere Giovanni | +16,734 | - | - |
| 2026-02-18 | Cecere Giovanni | +11,082 | - | - |
| 2026-01-23 | Corcoran Nicholas | -984 | $135.3 | $133,135 |
| 2025-12-04 | Hernandez Gerardo | -920 | $139.62 | $128,450 |
| 2025-12-03 | Weill David | -5,000 | - | - |
| 2025-12-03 | Weill David | -5,000 | $138.64 | $693,200 |
| 2025-12-03 | Weill David | +5,000 | $14.2 | $71,000 |
| 2025-11-25 | Ranganath Anil P. | -3,000 | - | - |
| 2025-11-25 | Ranganath Anil P. | -3,000 | $145.22 | $435,660 |
| 2025-11-25 | Ranganath Anil P. | +3,000 | $93.88 | $281,640 |
| 2025-11-17 | Hassanein Waleed H | +8,775 | $114 | $1,000,350 |
| 2025-10-29 | Basile Edward M | -4,142 | - | - |
| 2025-10-29 | Basile Edward M | -4,142 | $130.45 | $540,324 |
| 2025-10-29 | Basile Edward M | +4,142 | $0.7 | $2,899 |